A detailed history of Ubs Oconnor LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 13,600 shares of VKTX stock, worth $895,832. This represents 0.04% of its overall portfolio holdings.

Number of Shares
13,600
Holding current value
$895,832
% of portfolio
0.04%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$9.24 - $19.64 $330,459 - $702,404
-35,764 Reduced 61.76%
22,141 $412,000
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $174,720 - $256,000
16,000 Added 38.18%
57,905 $641,000
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $621,870 - $1.04 Million
41,905 New
41,905 $679 Million
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $955,896 - $2.05 Million
-118,304 Reduced 64.33%
65,608 $1.09 Million
Q4 2022

Feb 14, 2023

SELL
$2.72 - $9.4 $171,599 - $593,027
-63,088 Reduced 25.54%
183,912 $0
Q3 2022

Nov 14, 2022

BUY
$2.55 - $3.89 $629,850 - $960,830
247,000 New
247,000 $672 Million
Q1 2019

May 13, 2019

SELL
$7.58 - $9.94 $143,807 - $188,581
-18,972 Reduced 18.45%
83,870 $0
Q4 2018

Feb 15, 2019

BUY
$7.16 - $16.21 $56,148 - $127,118
7,842 Added 8.25%
102,842 $786,000
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $921,499 - $1.87 Million
95,000 New
95,000 $0

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.